HPGC(SH:600664) Zhi Tong Cai Jing·2026-02-05 07:39Core Viewpoint - The approval of the chemical raw material drug application for Ferric Succinate by the National Medical Products Administration marks a significant advancement for the company in the raw material drug sector, enhancing its strategic development and product structure [1] Group 1: Regulatory Approval - The company’s subsidiary, Harbin Pharmaceutical Group Sanjing Ming Water Pharmaceutical Co., Ltd., received the approval notice for Ferric Succinate from the National Medical Products Administration [1] - The approval number for the application is 2026YS00100 [1] Group 2: Strategic Implications - The approval signifies an important step in the company's layout within the raw material drug field, allowing for greater autonomy and control over its raw material production [1] - This development will further solidify the company's integrated strategy of raw material and formulation development, benefiting the diversification of its product offerings [1]